Given the abovementioned relations, the aim of our study was to evaluate COMP and YKL-40 concentrations in blood as potential markers of joint dysfunctions in patients with newly diagnosed JIA and in the same patients, both after clinical improvement, observed following an inflammation modifying therapy as well as in patients where the therapy prescribed did not result in remission. This evidence concerns the gene COMP and juvenile idiopathic arthritis.